Department of Urology, Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey.
Department of Urology, Prof. Dr Cemil Tascioglu City Hospital, Istanbul, Turkey.
Int J Clin Pract. 2021 Sep;75(9):e14584. doi: 10.1111/ijcp.14584. Epub 2021 Jul 9.
Our study aims to evaluate the efficiency and reliability of Vesical Imaging Reporting Data System (VI-RADS) in prospectively identifying the patients to undergo RE-TURBT in the management of patients with high-risk non-muscle invasive Bladder Cancer(HR-NMIBC).The secondary objective was to evaluate the performance of the VI-RADS scoring system in differentiating between muscle-invasive bladder cancer (MIBC) and non-muscle invasive bladder cancer(NMIBC) prospectively.
The study included 330 patients who underwent transurethral resection of bladder tumour(TURBT) for Bladder Cancer (BC) in our clinic. All patients underwent multiparametric-magnetic resonance imaging (Mp-MRI) before the operation and VI-RADS scoring was administered. The cut-off value of VI-RADS was accepted as three and above. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were calculated for the differentiation between NMIBC and MIBC distinction in all patients. Receiver operating characteristic (ROC) analysis was performed to evaluate the performance of the VI-RADS scoring system. In the second phase of the study, patients with MIBC and low-risk NMIBC (LR-NMBIC) were excluded and 158 patients with HR-NMIBC were included, and their sensitivity, specificity, PPV and NPV values were measured. ROC analysis was performed.
In all patients, sensitivity, specificity, PPV and NPV values of the VI-RADS scoring in the differentiation of MIBC and NMIBC were 91.3, 91.8, 81.7 and 96.3 respectively. The AUC value was 0.934 (95%CI: 0.903-0.964). Sensitivity, specificity, PPV and NPV values were found to be 87, 91.8, 74.1, 95.2 in the evaluation specifically made for patients with HR-NMIBC. The AUC value was 0.900 (95% CI:0.843-0.957). Inter-reader agreement was excellent (Ƙ = 0.90, 95% CI:0.71-0.95).
The VI-RADS scoring system is an effective and reliable method in determining the patients who will undergo RE-TURBT and in differentiating MIBC and NMIBC.
本研究旨在评估膀胱影像学报告数据系统(VI-RADS)在识别高危非肌层浸润性膀胱癌(HR-NMIBC)患者中进行再次经尿道膀胱肿瘤电切术(RE-TURBT)的效率和可靠性。次要目的是评估 VI-RADS 评分系统在区分肌层浸润性膀胱癌(MIBC)和非肌层浸润性膀胱癌(NMIBC)方面的性能。
本研究纳入了 330 例在我院接受经尿道膀胱肿瘤切除术(TURBT)治疗膀胱癌(BC)的患者。所有患者均在术前进行多参数磁共振成像(Mp-MRI)检查,并进行 VI-RADS 评分。将 VI-RADS 的截断值定义为 3 分及以上。计算所有患者中 NMIBC 和 MIBC 之间的区分的敏感性、特异性、阳性预测值(PPV)和阴性预测值(NPV)。进行受试者工作特征(ROC)分析以评估 VI-RADS 评分系统的性能。在研究的第二阶段,排除 MIBC 和低危非肌层浸润性膀胱癌(LR-NMBIC)患者,纳入 158 例 HR-NMIBC 患者,测量其敏感性、特异性、PPV 和 NPV 值。进行 ROC 分析。
在所有患者中,VI-RADS 评分在 MIBC 和 NMIBC 区分中的敏感性、特异性、PPV 和 NPV 值分别为 91.3%、91.8%、81.7%和 96.3%。AUC 值为 0.934(95%CI:0.903-0.964)。在专门针对 HR-NMIBC 患者的评估中,敏感性、特异性、PPV 和 NPV 值分别为 87%、91.8%、74.1%和 95.2%。AUC 值为 0.900(95%CI:0.843-0.957)。观察者间一致性极好(Ƙ=0.90,95%CI:0.71-0.95)。
VI-RADS 评分系统是一种有效且可靠的方法,可确定需要进行 RE-TURBT 的患者,并区分 MIBC 和 NMIBC。